Toiyama et al. evaluated the prognostic role of the pre-treatment plasma CRP level in a cohort of 84 rectal cancer patients and demonstrated that an elevated CRP level predicted poorer OS and early recurrence in patients with locally advanced rectal cancer treated with nRCT followed by total mesorectal excision (TME) [24]. The gene discussed is CRP; the disease is rectal cancer.